In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) is a therapeutic target for Acyclovir. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Acyclovir through regulating the expression of Alanine/serine/cysteine/threonine transporter 2 (SLC1A5).			[1], [2]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) is a therapeutic target for D-serine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of D-serine through regulating the expression of Alanine/serine/cysteine/threonine transporter 2 (SLC1A5).			[1], [3]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) is a therapeutic target for Ganciclovir. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Ganciclovir through regulating the expression of Alanine/serine/cysteine/threonine transporter 2 (SLC1A5).			[1], [2]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) is a therapeutic target for Glycine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Glycine through regulating the expression of Alanine/serine/cysteine/threonine transporter 2 (SLC1A5).			[1], [4]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) is a therapeutic target for L-carnitine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of L-carnitine through regulating the expression of Alanine/serine/cysteine/threonine transporter 2 (SLC1A5).			[1], [5]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) is a therapeutic target for L-glutamine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of L-glutamine through regulating the expression of Alanine/serine/cysteine/threonine transporter 2 (SLC1A5).			[1], [6]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) is a therapeutic target for Valacyclovir. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Valacyclovir through regulating the expression of Alanine/serine/cysteine/threonine transporter 2 (SLC1A5).			[1], [7]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) is a therapeutic target for Valganciclovir. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Valganciclovir through regulating the expression of Alanine/serine/cysteine/threonine transporter 2 (SLC1A5).			[1], [8]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) is a therapeutic target for Nitric oxide. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Nitric oxide through regulating the expression of Alanine/serine/cysteine/threonine transporter 2 (SLC1A5).			[1], [9]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) is a therapeutic target for L-threonine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of L-threonine through regulating the expression of Alanine/serine/cysteine/threonine transporter 2 (SLC1A5).			[1], [3]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) is a therapeutic target for benzylserine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of benzylserine through regulating the expression of Alanine/serine/cysteine/threonine transporter 2 (SLC1A5).			[1], [10]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) is a therapeutic target for p-nitrophenyl glutamyl anilide. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of p-nitrophenyl glutamyl anilide through regulating the expression of Alanine/serine/cysteine/threonine transporter 2 (SLC1A5).			[1], [11]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apolipoprotein E (APOE) is a therapeutic target for AEM-28. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of AEM-28 through regulating the expression of Apolipoprotein E (APOE).			[12], [13]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apolipoprotein E (APOE) is a therapeutic target for CN-105. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of CN-105 through regulating the expression of Apolipoprotein E (APOE).			[12], [14]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apolipoprotein E (APOE) is a therapeutic target for Apolipoprotein E. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Apolipoprotein E through regulating the expression of Apolipoprotein E (APOE).			[12], [15]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for VB-111. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of VB-111 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[16], [17]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APG-101. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of APG-101 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[16], [18]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for DE-098. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of DE-098 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[16], [19]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APO-010. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of APO-010 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[16], [20]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for 2-aminophenoxazine-3-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2-aminophenoxazine-3-one through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[16], [21]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APG-103. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of APG-103 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[16], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for F61F12. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of F61F12 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[16], [23]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for ISIS 17020. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of ISIS 17020 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[16], [24]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for MCI-186. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of MCI-186 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [26]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Venetoclax. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Venetoclax through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [27]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for ABT-263. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of ABT-263 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [28]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Oblimersen. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Oblimersen through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [29]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for RG7601. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of RG7601 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [30]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for APG-1252. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of APG-1252 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [32]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for APG-2575. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of APG-2575 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for AZD0466. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of AZD0466 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [34]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Beclanorsen. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Beclanorsen through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [35]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Gossypol. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Gossypol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [36]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Obatoclax. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Obatoclax through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[22], [25]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for PNT-2258. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of PNT-2258 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [37]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for AI-850. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of AI-850 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [38]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BCL201. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of BCL201 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [39]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BGB-11417. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of BGB-11417 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [40]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BP1002. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of BP1002 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [41]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for LP-108. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of LP-108 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [42]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Pc4. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Pc4 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [43]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for VOB560. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of VOB560 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 4,5-dibenzylbenzene-1,2-diol. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4,5-dibenzylbenzene-1,2-diol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [46]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [47]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Apogossypol. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Apogossypol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [48]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BP-100-1.02. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of BP-100-1.02 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [49]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for modified HA14-1 compounds (cancer). The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of modified HA14-1 compounds (cancer) through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [47]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [47]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for QEDIIRNIARHLAQVGDSMDR. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of QEDIIRNIARHLAQVGDSMDR through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [47]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for TW-37. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of TW-37 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [50]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for WL-276. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of WL-276 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [51]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for ABT-737. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of ABT-737 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[25], [52]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Aminoglutethimide. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Aminoglutethimide through regulating the expression of Aromatase (CYP19A1).			[53], [54]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Anastrozole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Anastrozole through regulating the expression of Aromatase (CYP19A1).			[53], [55]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Dehydroepiandrosterone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Dehydroepiandrosterone through regulating the expression of Aromatase (CYP19A1).			[53], [56]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Dihydrotestosterone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Dihydrotestosterone through regulating the expression of Aromatase (CYP19A1).			[53], [57]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Exemestane. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Exemestane through regulating the expression of Aromatase (CYP19A1).			[53], [58]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for FADROZOLE. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of FADROZOLE through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 2 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Letrozole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Letrozole through regulating the expression of Aromatase (CYP19A1).			[53], [60]
	Aromatase (CYP19A1) is a therapeutic target for Letrozole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Letrozole through regulating the expression of Aromatase (CYP19A1).			[53], [61]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Levomethadyl acetate hydrochloride. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Levomethadyl acetate hydrochloride through regulating the expression of Aromatase (CYP19A1).			[53], [62]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Methadone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Methadone through regulating the expression of Aromatase (CYP19A1).			[53], [63]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Nandrolone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Nandrolone through regulating the expression of Aromatase (CYP19A1).			[53], [64]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Testolactone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Testolactone through regulating the expression of Aromatase (CYP19A1).			[53], [58]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Testosterone cypionate. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Testosterone cypionate through regulating the expression of Aromatase (CYP19A1).			[53], [65]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for LIAROZOLE. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of LIAROZOLE through regulating the expression of Aromatase (CYP19A1).			[53], [66]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for BGS-649. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of BGS-649 through regulating the expression of Aromatase (CYP19A1).			[53], [67]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Coumate. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Coumate through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Naringenin. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Naringenin through regulating the expression of Aromatase (CYP19A1).			[53], [68]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for (2S)-5,7,2',4'-tetrahydroxyflavanone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of (2S)-5,7,2',4'-tetrahydroxyflavanone through regulating the expression of Aromatase (CYP19A1).			[53], [69]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for (2S)-abyssinone II. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of (2S)-abyssinone II through regulating the expression of Aromatase (CYP19A1).			[53], [69]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for (2S)-euchrenone a7. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of (2S)-euchrenone a7 through regulating the expression of Aromatase (CYP19A1).			[53], [69]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-(1-Benzyl-2-biphenyl-4-yl-ethyl)-1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-(1-Benzyl-2-biphenyl-4-yl-ethyl)-1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [70]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-(2-(benzo[b]thiophen-4-yl)ethyl)-1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-(2-(benzo[b]thiophen-4-yl)ethyl)-1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-(2-phenoxybenzyl)-1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-(2-phenoxybenzyl)-1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [72]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-(3-(4-fluorophenyl)propyl)-1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-(3-(4-fluorophenyl)propyl)-1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-(3-Methoxy-naphthalen-2-yl)-1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-(3-Methoxy-naphthalen-2-yl)-1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [73]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-(4-Aminophenyl)-2-(1H-imidazol-1-yl)ethanone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-(4-Aminophenyl)-2-(1H-imidazol-1-yl)ethanone through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-(4-Cyanobenzyl)-5-methyl-1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-(4-Cyanobenzyl)-5-methyl-1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-(4-nitro-2-phenoxybenzyl)-1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-(4-nitro-2-phenoxybenzyl)-1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [72]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-(4-Nitro-2-phenylsulfanylbenzyl)-1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-(4-Nitro-2-phenylsulfanylbenzyl)-1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [72]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-(7-Methoxy-2-phenyl-chroman-4-yl)-1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-(7-Methoxy-2-phenyl-chroman-4-yl)-1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [75]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-(9-phenyl-9H-fluoren-9-yl)-1H-1,2,4-triazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-(9-phenyl-9H-fluoren-9-yl)-1H-1,2,4-triazole through regulating the expression of Aromatase (CYP19A1).			[53], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-(9-Phenyl-9H-fluoren-9-yl)1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-(9-Phenyl-9H-fluoren-9-yl)1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-(9H-fluoren-9-yl)-1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-(9H-fluoren-9-yl)-1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-(biphenyl-3-ylmethyl)-1H-1,2,4-triazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-(biphenyl-3-ylmethyl)-1H-1,2,4-triazole through regulating the expression of Aromatase (CYP19A1).			[53], [77]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-Bromo-4-imidazol-1-ylmethyl-xanthen-9-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-Bromo-4-imidazol-1-ylmethyl-xanthen-9-one through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole through regulating the expression of Aromatase (CYP19A1).			[53], [78]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one through regulating the expression of Aromatase (CYP19A1).			[53], [79]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-Imidazol-1-ylmethylxanthen-9-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-Imidazol-1-ylmethylxanthen-9-one through regulating the expression of Aromatase (CYP19A1).			[53], [72]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-Naphthalen-2-yl-1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-Naphthalen-2-yl-1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [80]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 1-[(7-Fluoronaphth-2-yl)methyl]-1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 1-[(7-Fluoronaphth-2-yl)methyl]-1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 10-EPI-8-DEOXY-CUMAMBRIN B. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 10-EPI-8-DEOXY-CUMAMBRIN B through regulating the expression of Aromatase (CYP19A1).			[53], [81]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 11BETA,13-DIHYDRO-10-EPI-8-DEOXYCUMAM-BRIN B. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 11BETA,13-DIHYDRO-10-EPI-8-DEOXYCUMAM-BRIN B through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 2,3,4-Trimethoxy-4'-amino-trans-stilbene. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2,3,4-Trimethoxy-4'-amino-trans-stilbene through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 2,3,5-Trimethoxy-4'-amino-trans-stilbene. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2,3,5-Trimethoxy-4'-amino-trans-stilbene through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 2,3-Dimethoxy-4'-amino-trans-stilbene. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2,3-Dimethoxy-4'-amino-trans-stilbene through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 2,4-Dimethoxy-3'-amino-trans-stilbene. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2,4-Dimethoxy-3'-amino-trans-stilbene through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 2,4-Dimethoxy-4'-amino-trans-stilbene. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2,4-Dimethoxy-4'-amino-trans-stilbene through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 2,5-Dimethoxy-4'-amino-trans-stilbene. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2,5-Dimethoxy-4'-amino-trans-stilbene through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)ethanone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)ethanone through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 2-(3-hydroxyphenyl)-7-methoxychroman-4-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2-(3-hydroxyphenyl)-7-methoxychroman-4-one through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 2-(4-hydroxyphenyl)-7-methoxychroman-4-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2-(4-hydroxyphenyl)-7-methoxychroman-4-one through regulating the expression of Aromatase (CYP19A1).			[53], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 2-Imidazol-1-yl-7-methoxy-3-phenyl-chromen-4-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2-Imidazol-1-yl-7-methoxy-3-phenyl-chromen-4-one through regulating the expression of Aromatase (CYP19A1).			[53], [77]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 2-Imidazol-1-ylmethylxanthen-9-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2-Imidazol-1-ylmethylxanthen-9-one through regulating the expression of Aromatase (CYP19A1).			[53], [84]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 2-phenyl-2,3-dihydrobenzo[h]chromen-4-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2-phenyl-2,3-dihydrobenzo[h]chromen-4-one through regulating the expression of Aromatase (CYP19A1).			[53], [85]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 2-Phenyl-3-pyridin-4-ylmethylene-chroman-4-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2-Phenyl-3-pyridin-4-ylmethylene-chroman-4-one through regulating the expression of Aromatase (CYP19A1).			[53], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 2-Phenyl-4-[1,2,4]triazol-1-yl-chroman-7-ol. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2-Phenyl-4-[1,2,4]triazol-1-yl-chroman-7-ol through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3,4'-(Ethane-1,2-diyl)dibenzenamine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3,4'-(Ethane-1,2-diyl)dibenzenamine through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3,4,5-Trimethoxy-3'-amino-trans-stilbene. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3,4,5-Trimethoxy-3'-amino-trans-stilbene through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3,4,5-Trimethoxy-4'-amino-trans-stilbene. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3,4,5-Trimethoxy-4'-amino-trans-stilbene through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3,4-bis(3,4-dimethoxyphenyl)furan-2(5H)-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3,4-bis(3,4-dimethoxyphenyl)furan-2(5H)-one through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3,4-Dimethoxy-4'-amino-trans-stilbene. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3,4-Dimethoxy-4'-amino-trans-stilbene through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3,5-Diacetoxy-4'-amino-trans-stilbene. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3,5-Diacetoxy-4'-amino-trans-stilbene through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3,5-Diamino-4'-amino-trans-stilbene. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3,5-Diamino-4'-amino-trans-stilbene through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3,5-Dihydroxyl-4'-amino-trans-stilbene. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3,5-Dihydroxyl-4'-amino-trans-stilbene through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3,5-Dimethoxy-4'-amino-trans-stilbene. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3,5-Dimethoxy-4'-amino-trans-stilbene through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-((1H-imidazol-1-yl)methyl)-9H-xanthen-9-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-((1H-imidazol-1-yl)methyl)-9H-xanthen-9-one through regulating the expression of Aromatase (CYP19A1).			[53], [86]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [87]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [87]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(2,2-Diphenyl-vinyl)-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(2,2-Diphenyl-vinyl)-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(3,4-dihydronaphthalen-2-yl)pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(3,4-dihydronaphthalen-2-yl)pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [89]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [87]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(4-Amino-phenyl)-1-methyl-pyrrolidine-2,5-dione. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(4-Amino-phenyl)-1-methyl-pyrrolidine-2,5-dione through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione through regulating the expression of Aromatase (CYP19A1).			[53], [90]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(4-Amino-phenyl)-3-ethyl-pyrrolidine-2,5-dione. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(4-Amino-phenyl)-3-ethyl-pyrrolidine-2,5-dione through regulating the expression of Aromatase (CYP19A1).			[53], [91]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(4-Amino-phenyl)-3-heptyl-piperidine-2,6-dione. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(4-Amino-phenyl)-3-heptyl-piperidine-2,6-dione through regulating the expression of Aromatase (CYP19A1).			[53], [90]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(4-Amino-phenyl)-3-hexyl-piperidine-2,6-dione. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(4-Amino-phenyl)-3-hexyl-piperidine-2,6-dione through regulating the expression of Aromatase (CYP19A1).			[53], [92]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(4-Amino-phenyl)-3-methyl-pyrrolidine-2,5-dione. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(4-Amino-phenyl)-3-methyl-pyrrolidine-2,5-dione through regulating the expression of Aromatase (CYP19A1).			[53], [75]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione through regulating the expression of Aromatase (CYP19A1).			[53], [90]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(4-Amino-phenyl)-3-propyl-piperidine-2,6-dione. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(4-Amino-phenyl)-3-propyl-piperidine-2,6-dione through regulating the expression of Aromatase (CYP19A1).			[53], [90]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(4-Amino-phenyl)-pyrrolidine-2,5-dione. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(4-Amino-phenyl)-pyrrolidine-2,5-dione through regulating the expression of Aromatase (CYP19A1).			[53], [73]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [87]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(5-Bromo-6-methoxy-naphthalen-2-yl)-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(5-Bromo-6-methoxy-naphthalen-2-yl)-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [80]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(5-Chloro-6-methoxy-naphthalen-2-yl)-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(5-Chloro-6-methoxy-naphthalen-2-yl)-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(6-Ethoxy-naphthalen-2-yl)-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(6-Ethoxy-naphthalen-2-yl)-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [80]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [87]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(6-methoxynaphthalen-2-yl)pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(6-methoxynaphthalen-2-yl)pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [80]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(imidazolylmethyl)-4'-methoxyflavone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(imidazolylmethyl)-4'-methoxyflavone through regulating the expression of Aromatase (CYP19A1).			[53], [89]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(imidazolylmethyl)-4'-nitroflavone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(imidazolylmethyl)-4'-nitroflavone through regulating the expression of Aromatase (CYP19A1).			[53], [89]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(imidazolylmethyl)-7-methoxy-4'-nitroflavone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(imidazolylmethyl)-7-methoxy-4'-nitroflavone through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(imidazolylmethyl)flavone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(imidazolylmethyl)flavone through regulating the expression of Aromatase (CYP19A1).			[53], [89]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-(naphthalen-2-yl)pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(naphthalen-2-yl)pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [77]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-Amino-4'-amino-trans-stilbene. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-Amino-4'-amino-trans-stilbene through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-Fluoren-9-ylidenemethyl-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-Fluoren-9-ylidenemethyl-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol through regulating the expression of Aromatase (CYP19A1).			[53], [81]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-Indan-(1E)-ylidenemethyl-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-Indan-(1E)-ylidenemethyl-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [93]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-Indan-(1Z)-ylidenemethyl-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-Indan-(1Z)-ylidenemethyl-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-Methoxyl-4'-amino-trans-stilbene. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-Methoxyl-4'-amino-trans-stilbene through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-Nitro-4'-nitro-trans-stilbene. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-Nitro-4'-nitro-trans-stilbene through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[3-Methyl-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[3-Methyl-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[3-Methyl-indan-(1Z)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[3-Methyl-indan-(1Z)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[3-Phenyl-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[3-Phenyl-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[4-Chloro-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[4-Chloro-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[4-Chloro-indan-(1Z)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[4-Chloro-indan-(1Z)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[4-Fluoro-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[4-Fluoro-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[4-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[4-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[4-Methyl-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[4-Methyl-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[4-Methyl-indan-(1Z)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[4-Methyl-indan-(1Z)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[5-Ethoxy-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[5-Ethoxy-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[5-Ethoxy-indan-(1Z)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[5-Ethoxy-indan-(1Z)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 3-[7-Methoxy-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-[7-Methoxy-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol through regulating the expression of Aromatase (CYP19A1).			[53], [81]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4'-(Pyridin-4-ylmethyl)biphenyl-3-amine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4'-(Pyridin-4-ylmethyl)biphenyl-3-amine through regulating the expression of Aromatase (CYP19A1).			[53], [94]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4'-bromo-3-(imidazolylmethyl)-7-methoxyflavone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4'-bromo-3-(imidazolylmethyl)-7-methoxyflavone through regulating the expression of Aromatase (CYP19A1).			[53], [89]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4'-bromo-3-(imidazolylmethyl)flavone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4'-bromo-3-(imidazolylmethyl)flavone through regulating the expression of Aromatase (CYP19A1).			[53], [89]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4'-cyano-3-(imidazolylmethyl)-7-methoxyflavone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4'-cyano-3-(imidazolylmethyl)-7-methoxyflavone through regulating the expression of Aromatase (CYP19A1).			[53], [89]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4'-cyano-3-(imidazolylmethyl)flavone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4'-cyano-3-(imidazolylmethyl)flavone through regulating the expression of Aromatase (CYP19A1).			[53], [89]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-((1H-imidazol-1-yl)methyl)benzonitrile. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-((1H-imidazol-1-yl)methyl)benzonitrile through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-(1-Imidazol-1-yl-vinyl)-benzonitrile. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-(1-Imidazol-1-yl-vinyl)-benzonitrile through regulating the expression of Aromatase (CYP19A1).			[53], [86]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-(2,2-Diphenyl-vinyl)-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-(2,2-Diphenyl-vinyl)-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-(3,4,5-Trimethoxyphenethyl)aniline. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-(3,4,5-Trimethoxyphenethyl)aniline through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-(3,4-Dimethoxyphenethyl)aniline. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-(3,4-Dimethoxyphenethyl)aniline through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-(3,5-Dimethoxyphenethyl)benzenamine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-(3,5-Dimethoxyphenethyl)benzenamine through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-ANDROSTENE-3-17-DIONE. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-ANDROSTENE-3-17-DIONE through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-Fluoren-9-ylidenemethyl-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-Fluoren-9-ylidenemethyl-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-Imidazol-1-yl-2-phenyl-chroman-7-ol. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-Imidazol-1-yl-2-phenyl-chroman-7-ol through regulating the expression of Aromatase (CYP19A1).			[53], [95]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-Imidazol-1-ylmethyl-1-nitro-xanthen-9-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-Imidazol-1-ylmethyl-1-nitro-xanthen-9-one through regulating the expression of Aromatase (CYP19A1).			[53], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-Imidazol-1-ylmethyl-1-nitrothioxanthen-9-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-Imidazol-1-ylmethyl-1-nitrothioxanthen-9-one through regulating the expression of Aromatase (CYP19A1).			[53], [72]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-Imidazol-1-ylmethyl-2-nitroxanthen-9-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-Imidazol-1-ylmethyl-2-nitroxanthen-9-one through regulating the expression of Aromatase (CYP19A1).			[53], [72]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-Imidazol-1-ylmethyl-3-nitroxanthen-9-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-Imidazol-1-ylmethyl-3-nitroxanthen-9-one through regulating the expression of Aromatase (CYP19A1).			[53], [72]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-Imidazol-1-ylmethylthioxanthen-9-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-Imidazol-1-ylmethylthioxanthen-9-one through regulating the expression of Aromatase (CYP19A1).			[53], [72]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-Imidazol-1-ylmethylxanthen-9-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-Imidazol-1-ylmethylxanthen-9-one through regulating the expression of Aromatase (CYP19A1).			[53], [72]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-Indan-(1E)-ylidenemethyl-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-Indan-(1E)-ylidenemethyl-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-Indan-(1Z)-ylidenemethyl-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-Indan-(1Z)-ylidenemethyl-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [81]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [96]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-[6-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-[6-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 4-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 4-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 5-((1H-imidazol-1-yl)methyl)-7,8-dihydroquinoline. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 5-((1H-imidazol-1-yl)methyl)-7,8-dihydroquinoline through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 5-(2-(1H-imidazol-1-yl)ethyl)quinoline. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 5-(2-(1H-imidazol-1-yl)ethyl)quinoline through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one through regulating the expression of Aromatase (CYP19A1).			[53], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 5-Indan-(1E)-ylidenemethyl-1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 5-Indan-(1E)-ylidenemethyl-1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [92]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 5-Indan-(1Z)-ylidenemethyl-1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 5-Indan-(1Z)-ylidenemethyl-1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [92]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one through regulating the expression of Aromatase (CYP19A1).			[53], [97]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one through regulating the expression of Aromatase (CYP19A1).			[53], [77]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 5-[5-Bromo-indan-(1E)-ylidenemethyl]-1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 5-[5-Bromo-indan-(1E)-ylidenemethyl]-1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [92]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 5-[5-Bromo-indan-(1Z)-ylidenemethyl]-1H-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 5-[5-Bromo-indan-(1Z)-ylidenemethyl]-1H-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 5-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyrimidine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 5-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyrimidine through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 5-[5-Methoxy-indan-(1E)-ylidenemethyl]-thiazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 5-[5-Methoxy-indan-(1E)-ylidenemethyl]-thiazole through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 5-[5-Methoxy-indan-(1Z)-ylidenemethyl]-thiazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 5-[5-Methoxy-indan-(1Z)-ylidenemethyl]-thiazole through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 6-((1H-imidazol-1-yl)methyl)-2H-chromene-2-thione. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 6-((1H-imidazol-1-yl)methyl)-2H-chromene-2-thione through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 6-Imidazol-1-yl-isoquinoline. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 6-Imidazol-1-yl-isoquinoline through regulating the expression of Aromatase (CYP19A1).			[53], [72]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 7,4'-Dihydroxyflavone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 7,4'-Dihydroxyflavone through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 7-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 7-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one through regulating the expression of Aromatase (CYP19A1).			[53], [98]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one through regulating the expression of Aromatase (CYP19A1).			[53], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 7-((1H-imidazol-1-yl)methyl)isoquinoline. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 7-((1H-imidazol-1-yl)methyl)isoquinoline through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 7-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 7-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 7-hydroxy-2-(3-hydroxyphenyl)chroman-4-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 7-hydroxy-2-(3-hydroxyphenyl)chroman-4-one through regulating the expression of Aromatase (CYP19A1).			[53], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 7-hydroxy-2-phenylchroman-4-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 7-hydroxy-2-phenylchroman-4-one through regulating the expression of Aromatase (CYP19A1).			[53], [75]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 7-[1,2,4]Triazol-4-ylmethyl-chromen-4-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 7-[1,2,4]Triazol-4-ylmethyl-chromen-4-one through regulating the expression of Aromatase (CYP19A1).			[53], [75]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 8-Imidazol-1-ylmethyl-5-nitro-chromen-4-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 8-Imidazol-1-ylmethyl-5-nitro-chromen-4-one through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for 9-Hydroxy-7,8-benzoflavone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 9-Hydroxy-7,8-benzoflavone through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for ALBANOL A. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of ALBANOL A through regulating the expression of Aromatase (CYP19A1).			[53], [69]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for ALPHA-NAPHTHOFLAVONE. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of ALPHA-NAPHTHOFLAVONE through regulating the expression of Aromatase (CYP19A1).			[53], [80]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for ANDROSTENEDONE. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of ANDROSTENEDONE through regulating the expression of Aromatase (CYP19A1).			[53], [90]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for APIGENIN. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of APIGENIN through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Benzyl-biphenyl-4-ylmethyl-imidazol-1-yl-amine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Benzyl-biphenyl-4-ylmethyl-imidazol-1-yl-amine through regulating the expression of Aromatase (CYP19A1).			[53], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for biochanin A. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of biochanin A through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Broussoflavonol F. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Broussoflavonol F through regulating the expression of Aromatase (CYP19A1).			[53], [69]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for CGS-18320B. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of CGS-18320B through regulating the expression of Aromatase (CYP19A1).			[53], [99]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Chrysin. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Chrysin through regulating the expression of Aromatase (CYP19A1).			[53], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for DEHYDROLEUCODIN. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of DEHYDROLEUCODIN through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Docosapentaenoic acid. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Docosapentaenoic acid through regulating the expression of Aromatase (CYP19A1).			[53], [100]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for flavone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of flavone through regulating the expression of Aromatase (CYP19A1).			[53], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Gamma-mangostin. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Gamma-mangostin through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for GARCINONE D. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of GARCINONE D through regulating the expression of Aromatase (CYP19A1).			[53], [97]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for GOSSYPETIN. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of GOSSYPETIN through regulating the expression of Aromatase (CYP19A1).			[53], [70]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Isogemichalcone C. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Isogemichalcone C through regulating the expression of Aromatase (CYP19A1).			[53], [85]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for ISOLICOFLAVONOL. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of ISOLICOFLAVONOL through regulating the expression of Aromatase (CYP19A1).			[53], [69]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for LIQUIRTIGENIN. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of LIQUIRTIGENIN through regulating the expression of Aromatase (CYP19A1).			[53], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for LUDARTIN. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of LUDARTIN through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for MDL-18962. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of MDL-18962 through regulating the expression of Aromatase (CYP19A1).			[53], [101]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for MONODICTYOCHROMONE B. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of MONODICTYOCHROMONE B through regulating the expression of Aromatase (CYP19A1).			[53], [72]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for MORACHALCONE A. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of MORACHALCONE A through regulating the expression of Aromatase (CYP19A1).			[53], [69]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for MR-16089. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of MR-16089 through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for MR-20492. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of MR-20492 through regulating the expression of Aromatase (CYP19A1).			[53], [91]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for MR-20494. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of MR-20494 through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for MR-20496. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of MR-20496 through regulating the expression of Aromatase (CYP19A1).			[53], [73]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for MR-20814. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of MR-20814 through regulating the expression of Aromatase (CYP19A1).			[53], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for N-(2-benzyloxy-4-nitrophenyl)methanesulfonamide. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of N-(2-benzyloxy-4-nitrophenyl)methanesulfonamide through regulating the expression of Aromatase (CYP19A1).			[53], [87]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for N-(2-hexyloxy-4-nitrophenyl)methanesulfonamide. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of N-(2-hexyloxy-4-nitrophenyl)methanesulfonamide through regulating the expression of Aromatase (CYP19A1).			[53], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for N-(2-nonyloxy-4-nitrophenyl)methanesulfonamide. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of N-(2-nonyloxy-4-nitrophenyl)methanesulfonamide through regulating the expression of Aromatase (CYP19A1).			[53], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for N-(2-Propyloxy-4-nitrophenyl)methanesulfonamide. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of N-(2-Propyloxy-4-nitrophenyl)methanesulfonamide through regulating the expression of Aromatase (CYP19A1).			[53], [102]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for N-[2-(4'-Nitrophenyl)ethyl]-imidazole. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of N-[2-(4'-Nitrophenyl)ethyl]-imidazole through regulating the expression of Aromatase (CYP19A1).			[53], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-122427. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-122427 through regulating the expression of Aromatase (CYP19A1).			[53], [84]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-12999. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-12999 through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-131736. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-131736 through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-289311. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-289311 through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-356483. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-356483 through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-356781. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-356781 through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-368272. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-368272 through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-368280. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-368280 through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-369087. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-369087 through regulating the expression of Aromatase (CYP19A1).			[53], [81]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-613604. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-613604 through regulating the expression of Aromatase (CYP19A1).			[53], [84]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-625409. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-625409 through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-666292. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-666292 through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-683634. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-683634 through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-75308. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-75308 through regulating the expression of Aromatase (CYP19A1).			[53], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-93358. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-93358 through regulating the expression of Aromatase (CYP19A1).			[53], [67]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-94258. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-94258 through regulating the expression of Aromatase (CYP19A1).			[53], [69]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NSC-94891. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NSC-94891 through regulating the expression of Aromatase (CYP19A1).			[53], [84]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Org-33201. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Org-33201 through regulating the expression of Aromatase (CYP19A1).			[53], [103]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for FINROZOLE. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of FINROZOLE through regulating the expression of Aromatase (CYP19A1).			[53], [104]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for FORMESTANE. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of FORMESTANE through regulating the expression of Aromatase (CYP19A1).			[53], [105]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for MINAMESTANE. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of MINAMESTANE through regulating the expression of Aromatase (CYP19A1).			[53], [106]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for NKS-01. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NKS-01 through regulating the expression of Aromatase (CYP19A1).			[53], [107]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for Rogletimide. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Rogletimide through regulating the expression of Aromatase (CYP19A1).			[53], [108]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for VOROZOLE. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of VOROZOLE through regulating the expression of Aromatase (CYP19A1).			[53], [109]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Aromatase (CYP19A1) is a therapeutic target for YM-511. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of YM-511 through regulating the expression of Aromatase (CYP19A1).			[53], [110]